Hyperplasia News and Research RSS Feed - Hyperplasia News and Research

Endo resolves claims relating to vaginal mesh products

Endo resolves claims relating to vaginal mesh products

Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced that it has reached master settlement agreements with several of the remaining leading plaintiffs' law firms to resolve claims relating to vaginal mesh products sold by Endo's AMS subsidiary. [More]
Storage symptoms more severe in men with comorbid diabetes

Storage symptoms more severe in men with comorbid diabetes

A study of men with lower urinary tract symptoms and benign prostatic hyperplasia suggests that the presence of comorbid diabetes is associated with more severe urological symptoms. [More]
Experts share tips on prevention of prostate cancer

Experts share tips on prevention of prostate cancer

Prostate cancer is the second leading cause of cancer death in American men. One in seven men will be diagnosed with prostate cancer and 233,000 new cases are diagnosed annually. [More]
Physically active men are at lower risk of nocturia

Physically active men are at lower risk of nocturia

Men who are physically active are at lower risk of nocturia (waking up at night to urinate), according to a study led by a Loyola University Chicago Stritch School of Medicine researcher. [More]
Sorrento receives funding to advance immunotherapy targeting WISP1 for treatment of IPF

Sorrento receives funding to advance immunotherapy targeting WISP1 for treatment of IPF

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has received funding to advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) for the potential treatment of IPF, which affects more than 100,000 Americans. [More]
Risk of urinary tract infections after prostate biopsy highest in men with prior infections

Risk of urinary tract infections after prostate biopsy highest in men with prior infections

Risk of Urinary Tract Infections after Prostate Biopsy Highest in Men with Prior Infections or Significant Comorbidities, Report Swedish Researchers in The Journal Of Urology® [More]
Endo International revenues increase $719M to 1% in Q2 2014

Endo International revenues increase $719M to 1% in Q2 2014

Endo International plc today reported second quarter 2014 revenues of $719 million, an increase of 1 percent compared to second quarter 2013 revenues of $712 million. [More]
New toolkits help young adults navigate shift from pediatric to adult health care

New toolkits help young adults navigate shift from pediatric to adult health care

For young adults who have been diagnosed with a chronic condition like Type 1 diabetes or growth hormone deficiency, health concerns can add a degree of difficulty to transitions like leaving for college or living alone for the first time. [More]
Uroflowmetry reflects symptom severity in men with LUTS

Uroflowmetry reflects symptom severity in men with LUTS

Uroflowmetry is valuable for assessing disease severity in men with lower urinary tract symptoms due to benign prostatic hyperplasia, researchers believe. [More]
Study shows prevalence of uterine cancer in women undergoing hysterectomy procedure

Study shows prevalence of uterine cancer in women undergoing hysterectomy procedure

Among women undergoing a minimally invasive hysterectomy using electric power morcellation, uterine cancers were present in 27 per 10,000 women at the time of the procedure, according to a study published by JAMA. [More]
NANOG gene linked to tumours derived from stratified epithelia

NANOG gene linked to tumours derived from stratified epithelia

Scientists from the Spanish National Cancer Research Centre (CNIO) have discovered that NANOG, an essential gene for embryonic stem cells, also regulates cell division in stratified epithelia-those that form part of the epidermis of the skin or cover the oesophagus or the vagina-in adult organisms. [More]
Galderma's trifarotene molecule gets FDA Orphan Drug Designation for treatment of congenital ichthyosis

Galderma's trifarotene molecule gets FDA Orphan Drug Designation for treatment of congenital ichthyosis

Galderma announces that the U.S. FDA granted Orphan Drug Designation status for the company's trifarotene molecule for the treatment of congenital ichthyosis. Based on this decision, Galderma plans to implement a clinical development plan, reinforcing its commitment to exploring new treatment options for rare diseases, as well as meeting the needs of all patients with skin diseases over the course of their lives. [More]
Metabolic syndrome components may influence LUTS/BPH

Metabolic syndrome components may influence LUTS/BPH

Abdominal aortic calcification and visceral fat obesity each seem to influence lower urinary tract symptoms in men with benign prostatic hyperplasia, study findings suggest. [More]
Biomarkers help resolve differential diagnosis between MPM and non-cancerous pleural tissue

Biomarkers help resolve differential diagnosis between MPM and non-cancerous pleural tissue

Scientists have identified four biomarkers that may help resolve the difficult differential diagnosis between malignant pleural mesothelioma (MPM) and non-cancerous pleural tissue with reactive mesothelial proliferations (RMPs). [More]
Newborn congenital adrenal hyperplasia screening justified

Newborn congenital adrenal hyperplasia screening justified

The Swedish neonatal screening programme successfully detected all cases of clinically classified salt-wasting congenital adrenal hyperplasia during a 26-year period, researchers report. [More]
FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

Trimel Pharmaceuticals Corporation announced today that the United States Food and Drug Administration (FDA) has approved Natesto (testosterone), formerly CompleoTRT, the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. [More]
GSK reports positive results from Incruse Ellipta and Advair Diskus combination therapy in COPD patients

GSK reports positive results from Incruse Ellipta and Advair Diskus combination therapy in COPD patients

GlaxoSmithKline plc today presented data at the American Thoracic Society (ATS) from a late-stage clinical study. [More]
Noninvasive technique detects prostate cancer using an electronic nose

Noninvasive technique detects prostate cancer using an electronic nose

We may soon be able to make easy and early diagnoses of prostate cancer by smell. Investigators in Finland have established that a novel noninvasive technique can detect prostate cancer using an electronic nose. In a proof of principle study, the eNose successfully discriminated between prostate cancer and benign prostatic hyperplasia (BPH) by "sniffing" urine headspace (the space directly above the urine sample). Results using the eNose are comparable to testing prostate specific antigen (PSA), reports the Journal of Urology. [More]
GSK, Theravance announce availability of Anoro Ellipta in the US for COPD treatment

GSK, Theravance announce availability of Anoro Ellipta in the US for COPD treatment

GlaxoSmithKline plc and Theravance, Inc. today announced that Anoro Ellipta (umeclidinium and vilanterol inhalation powder), the first once-daily product approved in the US that combines two long-acting bronchodilators in a single inhaler for the maintenance treatment of chronic obstructive pulmonary disease (COPD), is now available to retail pharmacies in the US. [More]
Researchers discover hotspot L205R mutation is closely associated with adrenocortical tumors

Researchers discover hotspot L205R mutation is closely associated with adrenocortical tumors

Chinese researchers from Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, BGI, and other institutions have discovered that the activating hotspot L205R mutation in PRKACA gene was closely associated with adrenocortical tumors (ACTs), and the relationship of recurrently mutated DOT1L and CLASP2 with ACTs' other subtypes. [More]